Patents Examined by Bridget E. Bunner
  • Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15Ra and therapeutic uses thereof
    Patent number: 10906952
    Abstract: The present invention relates to fusion proteins comprising a binding protein and an IL-15 polypeptide as well as uses thereof, pharmaceutical compositions comprising such fusion proteins and a method for producing such fusion proteins.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: February 2, 2021
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, EBERHARD KARLS UNIVERSITÄT TÜBINGEN
    Inventors: Jung Gundram, Helmut Salih, Cornelia Lindner, Berit Lochmann
  • IL3Ralpha antibody conjugates and uses thereof
    Patent number: 10906979
    Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3R?) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3R?-expressing cell population, the methods comprising contacting a population of IL3R?-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3R?. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3R? chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3R?-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3R?.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: February 2, 2021
    Assignee: Stemline Therapeutics, Inc.
    Inventor: Ivan Bergstein
  • Tear lipocalin muteins binding IL-4 r alpha
    Patent number: 10898545
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: January 26, 2021
    Inventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
  • Anti-BAFFR antibody formulations and methods of use thereof
    Patent number: 10899841
    Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: January 26, 2021
    Assignee: NOVARTIS AG
    Inventors: Marta Cosenza, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
  • Targeting NCchannel for organ protection following ischemic episode
    Patent number: 10898496
    Abstract: The present invention concerns protection of an organ or tissue outside of the central nervous system following an ischemic episode. In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth. In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1. Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: January 26, 2021
    Assignees: University of Maryland, Baltimore, The United States of America as Represented by the Department of Veterans Affairs
    Inventor: J. Marc Simard
  • Human antibody specific for interleukin-1 alpha
    Patent number: 10899833
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: January 26, 2021
    Assignee: Janssen Biotech, Inc.
    Inventor: John Simard
  • Use of IL-15 to increase thymic output and to treat lymphopenia
    Patent number: 10894816
    Abstract: The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: January 19, 2021
    Assignee: The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: George N. Pavlakis, Barbara K. Felber, Antonio Valentin, Cristina Bergamaschi
  • Use of KIT inhibitors to condition subjects for a hematopoietic stem cell (HSC) transplantation
    Patent number: 10889646
    Abstract: Provided herein are compositions and methods related to conditioning a subject for a hematopoietic stem cell (HSC) transplantation using an inhibitor of a stem cell growth factor receptor (KIT). The compositions and methods described herein are particularly useful for a subject who is in need of a HSC transplantation and who is hypersensitive to at least one DNA damaging agent, e.g., a subject with fanconi anemia. Compositions and methods related to conditioning a fanconi anemia subject for HSC transplantation using an inhibitor of KIT are also provided herein.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: January 12, 2021
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Punam Malik, Shanmuganathan Chandrakasan
  • Nucleic acid encoding angiopoietin-2 specific Tie2 receptor
    Patent number: 10882895
    Abstract: In one aspect, provided herein is a polypeptide comprising a modified angiopoietin receptor or fragment thereof, wherein the polypeptide binds preferentially to angiopoietin-2 compared to angiopoeitin-1. Nucleic acid sequences encoding the polypeptide, as well as pharmaceutical uses of the polypeptide in treating diseases such as cancer and inflammation are also provided.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 5, 2021
    Assignee: UNITED KINGDOM RESEARCH AND INNOVATION
    Inventors: Nicolas Phillip James Brindle, Julian Edward Sale
  • Cationic liposomes for cancer immunotherapy
    Patent number: 10881612
    Abstract: Disclosed are positively-charged, cytotoxic nanoparticle compositions comprising immune modulators (such as the toll-like receptor (TLR)-4 ligand, monophosphoryl lipid (MPL)-A), and Interleukin (IL)-12)), which exhibit enhanced uptake by mammalian cancer cells, and cause increased cancer cell death and/or an increased release of cancer antigens following direct injection to populations of cancer or tumor cells. Also disclosed are nanoparticle-vectored, immunomodulatory compositions that stimulate antigen presenting immune cells and T cells, and support the development of anti-cancer immunity in mammalian hosts. The disclosed cationic liposomes represent an important advance in the area of cancer immunotherapeutics.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: January 5, 2021
    Assignee: The Methodist Hospital
    Inventors: Rita Elena Serda, Ismail Mustafa Meraz
  • Antagonists of IL-6 to prevent or treat thrombosis
    Patent number: 10875917
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: December 29, 2020
    Assignee: VITAERIS, INC.
    Inventor: Jeffrey T. L. Smith
  • Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
    Patent number: 10865230
    Abstract: The invention features soluble fusion protein complexes comprising at least two soluble fusion proteins. For example, the first fusion protein is an anti-CD3 antibody covalently linked to an interleukin-15 (IL-15) polypeptide or functional fragment thereof. The second fusion protein comprises a binding domain that recognizes disease antigens, wherein this domain is covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. One or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof, and the IL-15 domain of first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 15, 2020
    Assignee: ALTOR BIOSCIENCE, LLC
    Inventors: Bai Liu, Peter Rhode, Hing C. Wong
  • Synthetic notch protein for modulating gene expression
    Patent number: 10858443
    Abstract: Described herein are compositions, methods, and systems for modulating Notch receptor activation. Aspects of the invention relate to synthetic proteins comprising at least a Notch NRR (Negative Regulatory Region)-binding scFV fused to a transmembrane domain. Another aspect of the invention relates to drug-dependent synthetic proteins. Constructs and engineered cells comprising the synthetic proteins are additionally described herein.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: December 8, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventor: John T. Ngo
  • Methods and compositions for the treatment of radiation-related disorders
    Patent number: 10857200
    Abstract: This invention relates, in part, to methods and compositions that are useful for the treatment and/or prevention of various disorders, including radiation-related disorders, such as acute radiation syndrome.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: December 8, 2020
    Assignee: Cleveland BioLabs, Inc.
    Inventors: Vadim Krivokrysenko, Elena Feinstein
  • IL-18 binding protein (IL-18BP) in inflammatory diseases
    Patent number: 10858426
    Abstract: The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the indications.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: December 8, 2020
    Assignee: AB2 BIO SA
    Inventors: Andrea Pfeifer, Greg Del Val
  • Antibodies that bind interleukin-2 and uses thereof
    Patent number: 10858428
    Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: December 8, 2020
    Assignees: XOMA (US) LLC, MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Marina Roell, Mark Rubinstein, Hassan Issafras, Llewelyn Lao, Ou Li, Daniel H. Bedinger, Kristin Camfield Lind, Agnes Choppin Holmes, Toshihiko Takeuchi, Lauren Schwimmer, Hoa Giang, Amer M. Mirza, Kirk W. Johnson
  • Anti-IL-6 antibodies for the treatment of arthritis
    Patent number: 10858424
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat rheumatoid arthritis.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: December 8, 2020
    Assignee: ALDERBIO HOLDINGS LLC
    Inventor: Jeffrey T. L. Smith
  • IL22 immunoconjugates
    Patent number: 10858411
    Abstract: The application relates to a conjugate comprising interleukin-22 (IL22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ED-A isoform of fibronectin. In particular, the application relates to the therapeutic use of such conjugates in the treatment of a disease/disorder, such as autoimmune diseases, including inflammatory bowel disease (IBD).
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: December 8, 2020
    Assignee: Philogen S.P.A.
    Inventors: Franziska Sophie Bootz, Dario Neri
  • Method for the selection of antibodies against BCMA
    Patent number: 10851171
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: December 1, 2020
    Assignee: ENGMAB SARL
    Inventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein
    Patent number: 10842848
    Abstract: The present invention provides a medicine containing a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: November 24, 2020
    Assignee: Cytlimic Inc.
    Inventors: Tomoya Miyakawa, Shun Doi, Koji Tamada